FDA Approves First mRNA-Based Flu Vaccine for Adults

The U.S. Food and Drug Administration has approved Moderna's mRNA-based flu vaccine for adults aged 50-64, with accelerated approval for those 65 and older. This marks a significant regulatory action, introducing a new vaccine technology for influenza. The vaccine is based on the same messenger RNA platform as the COVID-19 vaccine.